Blog - Page 4853 of 5778

MondayApr 14, 2008 4:52 am

Global Roaming Distribution Inc. (GRDB.OB) Provides International Travelers with the Calling Comforts of Home

In today's technologically advanced society, you would be hard pressed to find someone who does not own a cellular phone. They enable us to stay connected to our integral networks no matter where we are in the country. Few of us, however, carry phones with affordable global-roaming capability; that's where Global Roaming Distribution’s Celtrek comes into play. Through the use of specially designed SIM cards, CelTrek provides the international traveler with the world's most full-featured global-roaming tools available. The chips offer voicemail, text messaging, call-forwarding and recording, conference-calls, and much more. Not only do they facilitate all of the everyday…

MondayApr 14, 2008 3:49 am

Business Definition Guides Monaco Coach Corp. (MNC) Stock Value

Technically, this stock is part of the Mobile Homes & RVs Industry in the Capital Goods Sector. Such a narrow stock market business definition is misleading for investors in this case. The stock shows its inherent value when we consider it as a service provider of better-value vacations. The company has creatively focused on Florida, California, and Nevada. This places its products in the heartland of resorts and the outdoors. The management has developed a broad range of offerings to meet most customer needs. The company has vehicles which can be towed, as well as motor coaches. It also has…

MondayApr 14, 2008 3:46 am

Mattson Technology Inc. (MTSN) – A Small Capital Gateway to the Semiconductors Industry

This stock has traded at the end of the second week of April 2008 at just $5.70. The Price to Earnings Ratio is below 11. Though institutions have firm grips on 95% of the stock, it is worth entering to whatever extent possible. The Semiconductors Industry has a sound, long-term future. The company recently received a major order from Asia to mark its entry in to the lucrative dielectric etching market. The company has an April 2008 market capitalization of less than $300 million. However, it is a giant and a leader in terms of its core technological competence. The…

FridayApr 11, 2008 6:57 pm

Cal-Maine Foods, Inc. (CALM.OB) Announces New Dividend Policy; Shares Shed 5.5%

Cal-Maine Foods, Inc. (CALM.OB), the largest poultry-egg producer in the United States, announced that the company will commence its new variable rate dividend policy for the third quarter of 2008. With record high egg prices, the company is pleased with the results from the third quarter of fiscal 2007. Demand for eggs remains elevated in both the retail and food service segments. In addition, demand for egg shells, used to produce liquid, frozen and dried egg products, has also been strong. Even with the higher prices, eggs still represent a good value to the consumer compared with other foods. However,…

FridayApr 11, 2008 6:55 pm

OTCPicks Featured Company: Intellect Neurosciences, Inc. (ILNS.OB) Obtains Notice of Allowance and Completes Grant Requirements

Intellect Neurosciences, Inc. (OTCBB: ILNS) announced that they have completed the grant requirements to obtain a European patent regarding the company's ANTISENILIN® antibodies product. They have also received a notice of allowance which states that future products to be developed by the company are approved for the treatment of Alzheimer's disease. The company's stock rose 68.75% during Thursday's trading, and an additional 7.41% April 11. The company has patents for their product, ANTISENILIN® antibodies, in Japan, China, and other countries to be disclosed. Currently, patent applications are in the approval stages in the United States. Dr. Daniel Chain, the company's…

FridayApr 11, 2008 3:39 pm

Transition Therapeutics Inc. (TTHI) Announces Licensing and Collaboration Agreement with Eli Lilly and Company

Transition Therapeutics Inc. (TTHI), based in Toronto, Ontario, Canada, is a biopharmaceutical company that develops novel therapeutics for diseases which affect large portions of the population. The focus of the company is discovering and advancing lead molecules to the most valuable and competitive targets in the industry using a state-of-the-art drug discovery engine, accelerating the development of multiple products for large disease indications, and generating shareholder value through partnership with major pharmaceutical companies. The company’s lead products are ELND005 for the treatment of Alzheimer’s disease, and TT-223 for the treatment of diabetes. The company announced a licensing and collaboration agreement…

FridayApr 11, 2008 12:40 pm

New Market China Inc. (NMCH.OB) Reviews 2007 Financial Results

New Market China, Inc., is a technology leader in the rapidly developing Chinese market specializing in software engineering, high quality software development, and digital multimedia outsourcing services delivered to customers globally. Yesterday the company’s CEO, John T. Verges, and CFO, Philip J. Rauch, conducted a webcast to review the Company's 2007 business operations and financial performance filed last week on SEC Form 10-KSB. The webcast is available in its entirety at: www.investorcalander.com. The company proudly reported total revenues of $40 million for 2007 a drastic 36% increase from only $29.5 million the prior year. Verges and Rauch reported that gross…

FridayApr 11, 2008 12:39 pm

Cell Genesys Inc. (CEGE) Sees Positive Cancer Test Results; Shares Jump 4%

Cell Genesys Inc. (CEGE) said Friday its GVAX immunotherapy treatment for recurrent prostate cancer did well in early stage clinical tests. Shares of the San Francisco, Calif.-based company were up nearly 4% to a high of $3.25 during late-day trading. Data from the trial, which enrolled 19 patients, indicate that GVAX helped 79% of the patients boost antibodies. In addition, the drug was generally well tolerated, with the most common side effects being injection-site reactions in most patients and mild flu-like symptoms in some patients, according to Cell Genesys. “We are now planning a larger randomized trial to further examine…

FridayApr 11, 2008 12:38 pm

Celgene International (CELG) Receives Approval from European Commission for the Treatment of Small Cell Lung Cancer

The European Commission (EC) today announced that Celgene’s amrubicin hydrochloride has been designated as an orphan medicinal product for the treatment of small cell lung cancer. This follows the European Medicines Agency's (EMEA) favorable opinion, issued by the EMEA's Committee for Orphan Medicinal Products (COMP). Amrubicin hydrochloride, a third generation drug, has already received approval and is now marketed in Japan for the treatment of both small cell lung cancer and non-small cell lung cancer by Nippon Kayaku. This official designation of amrubicin is important for Celgene because, once the designation is granted by the EC, it provides special incentives…

FridayApr 11, 2008 10:42 am

ZAP (ZAAP.OB) is at the Forefront of an Emerging Market

It is no secret that America and the rest of the world are heading toward a brick wall with regards to traditionally-powered automobiles. For decades, the idea of electric engines replacing current motor technology seemed far-fetched; but no more. Since 1994, ZAP has been an industry leader in alternative transportation technologies ranging from hybrid systems to hydrogen, ethanol, and fully-electric vehicle concepts. Their partnerships include a joint venture with Youngman Automotive, China's leading bus manufacturer which they call Detroit Electric, and design-collaboration with Lotus Engineering. In 2002, ZAP acquired Voltage Vehicles in a move which proved exponentially beneficial to distribution…

Site Search

Company Search